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ASSOCIATION LIKELY CAUSATIVE Hypomagnesemia
Hypomagnesemia associated with PPI use was first described in 2006 in patients who had been taking PPIs for more than 1 year and presented with carpopedal spasm. 2 Moreover, serum magnesium levels normalized with discontinuation of PPI therapy. Impaired absorption of magnesium may contribute to the development of hypomagnesemia. A metaanalysis of 9 observational studies and 109,798 patients reported a 43% increased risk of hypomagnesemia in patients receiving PPIs, thus suggesting a causative association. 3 In 2011, the US Food and Drug Administration (FDA) issued a safety warning regarding the association between PPI use and hypomagnesemia and recommended monitoring of magnesium levels in patients receiving long-term PPI therapy. Some guidelines suggest monitoring patients, particularly those concomitantly using diuretics or those with malabsorption disorders, because PPIs appear to be causative in this relationship. acid production associated with PPI use can lead to overgrowth of small-intestine bacteria.
Vitamin
A meta-analysis of 11 studies found an increased risk for development of SIBO among PPI users compared with nonusers (OR, 2.28; 95% CI, 1.24-4.21). This risk was 7.5-times greater among studies that utilized the more sensitive and specific duodenal/jejunal aspirate for diagnosis of SIBO. Studies using the glucose hydrogen breath test for diagnosis, a less sensitive and less specific technique, did not find this relationship. 6 We suspect that this association is likely causative, although the clinical importance of SIBO remains controversial.
ASSOCIATION UNCLEAR Bone Fractures
Osteoporosis-related fractures are a major health concern associated with significant morbidity and mortality: the lifetime risk is approximately 40% to 50% and 13% to 22% for females and males, respectively.
7 Based on data from observational studies, concern has grown over the potential association between long-term use of PPIs and fracture risk. In 2010, the FDA published a warning of the increased risk of PPI use and fractures of the spine, wrist, and hip.
Multiple studies have found an increased risk of bone fractures in PPI users. A recent meta-analysis of 18 observational studies revealed that PPI use was associated with a 33% increased risk for fracture at any site (RR, 1.33; 95% CI, 1.15-1.54), a 26% higher risk of hip fracture (RR, 1.26; 95% CI, 1.16-1.36), and a 58% increase in risk of spine fracture (RR, 1.58; 95% CI, 1.38-1.82). After limiting analysis to cohort studies, and thus eliminating heterogeneity, the risk of hip fracture was still moderately increased by 24%. Subgroup analysis, interestingly, found that both short-term (<1 year) and long-term use were associated with increased risk of hip fracture. 8 The proposed mechanism for the increased fracture risk in patients receiving PPI therapy is reduced calcium absorption resulting in decreased bone mineral density (BMD). A placebo-controlled, double-blind, crossover trial in elderly postmenopausal women found that calcium carbonate absorption in the fasting state decreased after 1 week of omeprazole therapy. 9 However, there is no clear evidence that PPI medications are associated with development of osteoporosis. The most thorough study assessed the relationship between PPI use and BMD of the lumbar spine (vertebrae L1-L4), femoral neck, and total hip at baseline and after 5 years and 10 years of PPI use. 10 A total of 8340 patients underwent initial BMD measurements, and 4512 patients completed BMD testing after 10 years. After adjusting for confounders, the results revealed that BMD was significantly lower at the total hip and femoral neck regions but not at the lumbar spine among individuals using PPIs at baseline. After regression analyses, among those patients receiving continuous PPI therapy, there was no significant rate of change in BMD at the previously described measurement sites over 5-and 10-year periods. Similar to other studies, PPI users had significantly higher fracture rates compared with nonusers at baseline, but this finding was likely impacted by having statistically lower overall BMD as well as risk factors that predispose to fracture, including older age, female sex, and concurrent use of medications including corticosteroids. Finally, the association of short-term PPI use with fractures similarly suggests that PPI-induced osteoporosis is not likely the cause of PPI-associated bone fractures.
Another hypothesized mechanism is the inhibition of osteoclastic activity by PPIs, which affect bone remodeling and structure. A study of 104 patients (52 PPI users for 5 years and 52 nonusers) found no significant differences between the 2 populations in mean T scores of the femoral neck, trochanter, total hip, and L1 through L4 vertebrae or in overall BMD, cortical or trabecular BMD, and cortical thickness, therefore concluding that long-term use of PPIs was not associated with adverse changes to bone structure. 11 Additionally, the relationship between PPI use and risk of fracture among 79,899 postmenopausal women differed only by smoking history; while current and former smokers had a 50% increased risk of fracture, there was no significant increase in fracture risk among nonsmokers who used PPIs. 12 Although these studies have linked PPI use to development of hip fractures, recent data have been inconsistent and suggest that although there may be a mild to moderate increase in the overall risk of fractures regardless of duration of therapy, long-term PPI use does not significantly affect the rate of bone density loss. However, clinicians should be aware of the potential for association with fracture risk, although the American Gastroenterological Association does not recommend routine BMD screening or increased calcium supplementation in patients receiving longterm PPI therapy. 13 
Clostridium difficile Infection
Clostridium difficile is a common cause of diarrhea associated with increasing morbidity and mortality. Studies have suggested a link between use of PPIs and development of C difficile infection (CDI), which led the FDA to issue a warning regarding risk of CDI in patients receiving PPI therapy and also recommend use of the lowest PPI dose for the shortest duration. A meta-analysis of 42 observational studies revealed an increased risk of both incident and recurrent CDIs in patients treated with PPIs (OR, 1.74; 95% CI, 1.47-2.85 and OR, 2.51; 95% CI, 1.16-5.44, respectively).
14 Although presenting less overall risk, the use of histamine 2 receptor antagonists was also associated with an increased risk for CDI, thus suggesting an overall role of acid suppression in development of CDI. All studies included were nonrandomized observational studies, had significant statistical heterogeneity, and were variable with regard to dose and duration of PPI treatment.
The association between CDI and PPI use is hypothesized to be due to survival of the C difficile vegetative form in the alkaline gastric pH. The emergence of SIBO in PPI users increases the luminal concentration of unconjugated bile acids, which may lead to conversion of the C difficile spores to the toxin-secreting vegetative form. Additionally, after 4 to 8 weeks of PPI therapy, there are alterations in the gut microbiome that predispose patients to development of CDI. 15 A review of 23 observational studies with 288,620 patients found a 65% increase in CDI incidence among patients receiving PPIs. 16 An association between PPI use and CDI recurrence has also been reported. 17 However, studies with additional multivariate analysis established that PPI use was not associated with an increase in severe, complicated CDI, treatment failure, or recurrence of CDI. Hence, the association between PPI use and CDI has been inconsistent, suggesting an association without clear causation.
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Acute and Chronic Kidney Disease
Reports have raised concerns regarding an association between use of PPIs and both acute kidney injury (AKI) and chronic kidney disease (CKD). In the prospective Atherosclerosis Risk in Communities Study, 10,482 participants with normal baseline renal function were followed up for a median of 13.9 years. 19 After adjusted analysis, the results revealed that PPI users had a 50% greater risk of development of CKD than nonusers, with a 10-year absolute risk increase of 3.3%. There was also a 64% increased risk of AKI among PPI users. These findings were replicated in a cohort of 248,751 patients from the Geisinger Health System who were followed up for a median of 6.2 years, during which there was a 17% increased risk of CKD among PPI users and higher risk with twice-daily dosing of PPIs when compared with a single daily dose. 19 However, among this population, there was a statistically significant increase in concomitant use of NSAIDs among PPI users, which is a confounding variable. The strengths of this study were inclusion of adjusted multivariate analysis and comparison between PPI users with propensity scoreematched nonusers. Using the Department of Veterans Affairs national databases, Xie et al 20 also assessed renal outcomes among a cohort of 173,321 new PPI users vs 20,270 new users of histamine 2 receptor antagonists followed up for a period of 5 years. In comparison with patients using histamine 2 receptor antagonists, PPI users had a 28% increased risk for incident CKD, as well as increased risk for estimated glomerular filtration rate decline greater than 30%, doubling of serum creatinine level, and development of end-stage renal disease. 20 There was also a significant association between duration of exposure and worsening outcomes. Another population-based study of 290,592 patients older than 65 years found a 2.5-times increased risk for development of AKI and a 3-times increased risk for acute interstitial nephritis among elderly patients recently beginning PPI therapy. 21 Similarly, in a recent retrospective population study from Sweden, the risk of doubling of the serum creatinine level was 1.26-times greater after initiating PPI therapy compared with histamine 2 receptor antagonist therapy over a median follow-up of 2.7 years. 22 The mechanism for development of CKD may be the result of subclinical acute interstitial nephritis, which if untreated progresses to injury of the nephron. Based on the results of these studies, initiation and cumulative use of PPIs have been associated with risk for kidney disease. No recommendations have been proposed for monitoring kidney function in patients receiving long-term PPI therapy, irrespective of dose. We believe that until this association is better clarified, it is reasonable to monitor estimated glomerular filtration rate annually, based on CKD guidelines for monitoring patients taking potentially nephrotoxic medications. 23 Dementia Recent observational studies have suggested an increased risk of dementia among PPI users. Two prospective studies have assessed the association between PPI use and the risk of dementia. Haenisch et al 24 studied 3076 patients 75 years or older with no history of dementia and after adjusting for confounders, found that PPI users had a 38% increased risk of dementia and a 44% increased risk of Alzheimer disease. Gomm et al 25 similarly conducted a prospective cohort study of 73,679 individuals 75 years or older without dementia at baseline and also found a significant 44% increased risk of dementia among patients receiving regular PPI medication. These findings contrast those of a recent prospective analysis of 13,864 middle-aged and older women enrolled in the Nurses' Health Study II, in which there was no definite evidence of association between the duration of PPI use and cognitive function. 26 Data from the Finnish nationwide health care registry also reported that among 70,718 newly diagnosed cases of Alzheimer disease, PPI use was not associated with increased risk. 27 Accumulation of amyloid-b peptides is involved in the pathogenesis of Alzheimer disease, and studies have found that lansoprazole led to higher levels of amyloid-b levels in the brains of mice. 28 The PPIs increase amyloid synthesis and decrease amyloid degradation in the brain. In addition, association of PPI use with vitamin B 12 deficiency can lead to neurologic symptoms including dementia. Thus, prospective clinical trials are required to further examine and establish this causal association.
ASSOCIATION UNLIKELY CAUSATIVE
Several studies have reported an association between PPI use and development of communityacquired pneumonia (CAP). 29 A meta-analysis of 8 observational studies found that the overall risk of pneumonia was increased by 27% with use of PPIs. 30 There was a temporal relationship of pneumonia with recent initiation of PPI treatment (7 days of index date). This temporal relationship would support a confounding rather than causative association between PPI use and CAP. Further subgroup analyses revealed that higher doses were correlated with greater risk of development of pneumonia and that this risk decreased with longer duration of therapy before the index date of diagnosis. To address the limitations of prior studies and examine the risk between PPIs and CAP, a meta-analysis of 8 cohort studies was conducted in patients initiating prophylactic PPIs while using NSAIDs. Results revealed that PPIs were not associated with increased risk of hospitalization for CAP in the 6 months immediately following initiation of NSAID therapy (OR, 1.05; 95% CI, 0.89-1.25). 31 A recently published observational cohort study noted an increased risk of mortality with PPI use. However, this study had major limitations including the potential for residual confounders accounting for this association, selection bias, and limited generalizability of results. 32 Although we should not ignore these epidemiological associations, prospective controlled studies are needed in the future to establish a causative relationship between PPIs and the aforementioned diseases.
CONCLUSION
Use of PPIs has been reported to be associated with increased risk for development of a multitude of adverse effects. The majority of the data are based on results from retrospective observational studies, which have inherent biases, risk for confounding variables, and the inability to demonstrate a definite causal relationship. Most of these studies reported mild to moderate overall associations (with RRs of 1 to 2) between PPI use and the risks of bone fracture, CDI, pneumonia, vitamin and mineral deficiencies, kidney disease, and dementia. Thus, because many of these adverse effects are uncommon, the absolute risk to patients remains quite small.
Based on current recommendations, the American Gastroenterological Association does not recommend routine laboratory monitoring or use of supplemental calcium, vitamin B12, and magnesium in patients taking PPIs daily. However, as this story evolves, our current practice is to check creatinine levels yearly, complete blood cell counts every other year, and vitamin B12 levels every 5 years in patients receiving long-term PPI therapy. In summary, the best strategy is to prescribe PPIs at the lowest dose on a short-term basis when appropriately indicated so that the potential benefits outweigh any adverse effects associated with the use of PPIs.
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